To receive the Femtech World newsletter, sign up here.
News
OB/GYN platform secures US$20m to tackle ‘unmet needs’ in pelvic health
Materna Medical seeks to transform the standard of care in OB/GYN in the United States
The OB/GYN platform Materna Medical has raised US$20m in funding to tackle the unmet needs in women’s pelvic health in the US.
Materna Medical aims to use technology to “transform” the standard of care in OB/GYN and empower women to protect their pelvic health.
The start-up’s first product, Milli, is a device designed to support women suffering from vaginismus and related painful sex.
The company’s second product, Materna Prep, is an investigational device used during labour and is intended to reduce pelvic floor muscle injury during vaginal delivery. It has shown promise in the potential to reduce pelvic floor injury rates for women delivering vaginally.
The US$20m round, led by InnovaHealth Partners with participation from Wavemaker Three-Sixty Health, Kimera Limited, Women’s Venture Capital Fund, Golden Seeds, Band of Angels and Houston Angel Network, is hoped to help the California-based start-up expand and support the commercial launch of Materna Prep.
Tracy MacNeal, chief executive officer of Materna Medical, said: “Materna is a first mover, aiming to transform the standard of care in labour and delivery. Imagine a world in which women aren’t injured while delivering vaginally.
“Our nation’s maternal health crisis is a clarion call for new obstetrical technologies, and Materna is leading the way.”
Dr Ariella Golomb, Materna’s board chair and partner at InnovaHealth Partners, shared: “We are pleased with the company’s progress, excited about the feasibility data and look forward to its publication later this year.
“The funds from Series B2 will be used to obtain FDA marketing authorisation for Materna Prep and support the commercial launch of this transformative technology.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Wellness3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Diagnosis2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now







9 Comments